Klaus Fellermann

Summary

Country: Germany

Publications

  1. ncbi request reprint Response of refractory colitis to intravenous or oral tacrolimus (FK506)
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Inflamm Bowel Dis 8:317-24. 2002
  2. pmc A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Hospital, 70376 Stuttgart, Germany
    Am J Hum Genet 79:439-48. 2006
  3. ncbi request reprint Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Krankenhaus, Stuttgart, Germany
    Inflamm Bowel Dis 9:198-201; discussion 202-4. 2003
  4. pmc Reduced mucosal antimicrobial activity in Crohn's disease of the colon
    Sabine Nuding
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376 Stuttgart, Germany
    Gut 56:1240-7. 2007
  5. pmc Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease
    Maureen J Koslowski
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, Germany
    PLoS ONE 4:e4496. 2009
  6. ncbi request reprint Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis
    Klaus R Herrlinger
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Inflamm Bowel Dis 10:229-33. 2004
  7. pmc Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin
    Miriam Schlee
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Infect Immun 75:2399-407. 2007
  8. pmc Crohn's disease--defect in innate defence
    Michael Gersemann
    Internal Medicine I, Robert Bosch Hospital, Auerbachstrasse 110, Stuttgart, Germany
    World J Gastroenterol 14:5499-503. 2008
  9. pmc The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease
    Frauke Borcherding
    Department of Internal Medicine I, University Hospital of Schleswig Holstein, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Am J Pathol 176:1816-27. 2010
  10. doi request reprint Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3
    Sabine Nuding
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology Stuttgart and University of Tuebingen, Auerbachstr 112, 70376 Stuttgart, Germany
    Microbes Infect 11:384-93. 2009

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Response of refractory colitis to intravenous or oral tacrolimus (FK506)
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Inflamm Bowel Dis 8:317-24. 2002
    ..Renal impairment was rare and subsided upon drug withdrawal. In conclusion. FK506 is effective in the treatment of refractory colitis with per oral dosing being equivalent to intravenous administration...
  2. pmc A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Hospital, 70376 Stuttgart, Germany
    Am J Hum Genet 79:439-48. 2006
    ..033). In conclusion, a lower HBD-2 gene copy number in the beta-defensin locus predisposes to colonic CD, most likely through diminished beta-defensin expression...
  3. ncbi request reprint Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Krankenhaus, Stuttgart, Germany
    Inflamm Bowel Dis 9:198-201; discussion 202-4. 2003
  4. pmc Reduced mucosal antimicrobial activity in Crohn's disease of the colon
    Sabine Nuding
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376 Stuttgart, Germany
    Gut 56:1240-7. 2007
    ..To elucidate the possible functional consequences of this deficiency antimicrobial activity in colonic mucosa from patients with inflammatory bowel disease and healthy controls was investigated...
  5. pmc Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease
    Maureen J Koslowski
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, Germany
    PLoS ONE 4:e4496. 2009
    ..38, 95% CI 1.03 to1.84, p = 0.02882). The newly identified genetic association of TCF-4 with ileal CD provides evidence that the decrease in Paneth cell alpha-defensins is a primary factor in disease pathogenesis...
  6. ncbi request reprint Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis
    Klaus R Herrlinger
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Inflamm Bowel Dis 10:229-33. 2004
    ..In addition, because standard laboratory inflammatory parameters are poorly correlated with disease activity in IBD, the relation between PCT levels and disease activity was investigated...
  7. pmc Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin
    Miriam Schlee
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Infect Immun 75:2399-407. 2007
    ..coli strain ATCC 25922. H1 flagellin antiserum abrogated hBD-2 expression induced by flagellin as well as E. coli Nissle 1917 supernatant, confirming that flagellin is the major stimulatory factor of E. coli Nissle 1917...
  8. pmc Crohn's disease--defect in innate defence
    Michael Gersemann
    Internal Medicine I, Robert Bosch Hospital, Auerbachstrasse 110, Stuttgart, Germany
    World J Gastroenterol 14:5499-503. 2008
    ..A better understanding of the exact molecular mechanisms behind ileal and colonic Crohn's disease may give rise to new therapeutic strategies based on a stimulation of the protective innate immune system...
  9. pmc The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease
    Frauke Borcherding
    Department of Internal Medicine I, University Hospital of Schleswig Holstein, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Am J Pathol 176:1816-27. 2010
    ..Our findings provide evidence for the epithelial expression and modulation of CD40 in IBD-affected mucosa and indicate its involvement in the proinflammatory function of IECs...
  10. doi request reprint Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3
    Sabine Nuding
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology Stuttgart and University of Tuebingen, Auerbachstr 112, 70376 Stuttgart, Germany
    Microbes Infect 11:384-93. 2009
    ..Thus, defensin resistance is not only species- but also strain-specific and may be clinically relevant in the host-bacteria interaction influencing mucosal translocation and systemic infection...
  11. doi request reprint Cyclophosphamide therapy in Sweet's syndrome complicating refractory Crohn's disease − Efficacy and mechanism of action
    Christian Meinhardt
    Department of Internal Medicine I, University Hospital Schleswig Holstein, Campus Lubeck, Germany
    J Crohns Colitis 5:633-7. 2011
    ..The mechanism of action remains obscure. Here, we report about a case of steroid-refractory Sweet's syndrome accompanying Crohn's colitis treated by cyclophosphamide...
  12. ncbi request reprint Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease
    Michael Schmid
    Department of Internal Medicine I, Robert Bosch Hospital, Auerbachstr 112, 70376 Stuttgart, and Department of Dermatology, University of Kiel, Germany
    J Leukoc Biol 81:907-15. 2007
    ..This could contribute to the transmural depth of tissue destruction in CD. Elafin and SLPI may be added to the list of defensin-like peptides with diminished induction in CD versus UC...
  13. doi request reprint Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis
    Michael Gersemann
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Differentiation 77:84-94. 2009
    ..Conspicuously, inflammation is associated with an enhanced goblet cell differentiation in CD but not in UC, a defect possibly of pathogenic importance...
  14. ncbi request reprint A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts
    Sabine Nuding
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Robert Bosch Hospital, Auerbachstr 110, 73061 Stuttgart, Germany
    J Microbiol Methods 65:335-45. 2006
    ..coli at 150 mM NaCl, whereas the activity towards S. aureus ATCC 25923 remained unaffected at physiological salt concentrations. DTT blocked the bactericidal effect of biopsy extracts completely...
  15. ncbi request reprint Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis
    Jan Wehkamp
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Inflamm Bowel Dis 9:215-23. 2003
    ..The missing induction of both inducible beta-defensins in CD as compared with UC may cause a defect in barrier function that predisposes to bacterial invasion...
  16. ncbi request reprint Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease
    Jan Wehkamp
    Department of Internal Medicine I, Division of Gastroenterology, University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    Eur J Gastroenterol Hepatol 14:745-52. 2002
    ..This study investigated beta-defensin mRNA and peptide expression in the colon from controls and patients with Crohn's disease, ulcerative colitis or unspecific colitis as inflammatory controls...
  17. ncbi request reprint Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease
    Nils Homann
    Department of Internal Medicine I, Division of Gastroenterology, University of Schleswig Holstein Campus Lubeck, Lubeck, Germany
    Inflamm Bowel Dis 11:126-32. 2005
    ....
  18. pmc NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium
    Jan Wehkamp
    Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
    Infect Immun 72:5750-8. 2004
    ..The induction of hBD-2 may contribute to an enhanced mucosal barrier to the luminal bacteria...
  19. ncbi request reprint Crohn's disease: a defensin deficiency syndrome?
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Krankenhaus, Stuttgart, Germany
    Eur J Gastroenterol Hepatol 15:627-34. 2003
    ..The hypothesis of an impaired mucosal antibacterial activity is also consistent with the benefit from antibiotic or probiotic treatment in certain inflammatory bowel disease states...
  20. ncbi request reprint The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4
    Jan Wehkamp
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstrasse 12, Stuttgart, Germany
    J Immunol 179:3109-18. 2007
    ..This new link established between a human inflammatory bowel disease and the Wnt pathway/Tcf-4 provides a novel mechanism for pathogenesis in patients with ileal CD...
  21. ncbi request reprint The expression patterns of peritoneal defensins
    Alexander Grupp
    Division of General Internal Medicine and Nephrology, Department of Internal Medicine, Robert Bosch Krankenhaus, Auerbachstrasse 110, Stuttgart, Germany
    Perit Dial Int 27:654-62. 2007
    ..Local defense mechanisms are important for the integrity of the peritoneum, but few details are known about the expression patterns of antimicrobial proteins such as human defensin in normal and damaged peritoneum...
  22. ncbi request reprint Crohn's targeted therapy: myth or real goal?
    Klaus J Schmidt
    Department of Internal Medicine I, University Hospital of Schleswig Holstein, Ratzeburger Allee 160, D 23538 Lubeck, Germany
    Curr Drug Discov Technol 6:290-8. 2009
    ..Hence, targeted therapy in CD seems to be still a myth at present owing to the complex nature of disease...
  23. ncbi request reprint Fatal staphylococcal sepsis in Crohn's disease after infliximab
    Klaus R Herrlinger
    Department of Internal Medicine, Robert Bosch Hospital, Stuttgart, Germany
    Inflamm Bowel Dis 10:655-6. 2004
    ..After six infusions of infliximab, the patient developed staphylococcal pneumonia resulting in fatal adult respiratory distress syndrome. The case is discussed in the context of the toxicity profile of infliximab...
  24. doi request reprint Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4
    Martin Nitschke
    Department of Internal Medicine I, University Hospital Schleswig Holstein, Campus Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany
    JAMA 307:1046-52. 2012
    ..In the German outbreak, a substantial number of patients received prophylactic azithromycin treatment as part of a therapeutic regimen with the C5 antibody eculizumab...
  25. ncbi request reprint Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections
    Marco Oliver Schunter
    Department of Gastroenterology and Hepatology, Robert Bosch Hospital, Auerbachstrasse 110, 70376 Stuttgart, Germany
    J Crohns Colitis 1:41-6. 2007
    ..Herpes simplex virus colitis is a rare but potentially fatal complication of immunosuppressive treatment in patients with inflammatory bowel disease. Prompt diagnosis and efficient antiviral therapy are mandatory to improve prognosis...
  26. ncbi request reprint Adverse events of tumor necrosis factor inhibitors
    Klaus Fellermann
    Division of Gastroenterology, Department of Internal Medicine I, University Hospital of Schleswig Holstein, Lubeck, Germany
    Dig Dis 31:374-8. 2013
    ..Last but not least, there is the unresolved question of tumor induction and propagation. All of these may account for morbidity and eventually mortality...
  27. ncbi request reprint Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases
    Jürgen Schauber
    Department of Medicine II, Division of Gastroenterology cInstitute of Pathology, University of Wurzburg, Germany
    Eur J Gastroenterol Hepatol 18:615-21. 2006
    ..In this study, the expression of human cathelicidin hCAP18/LL-37 was investigated in the intestinal mucosa from patients suffering from ulcerative colitis or Crohn's disease...
  28. pmc Reduced Paneth cell alpha-defensins in ileal Crohn's disease
    Jan Wehkamp
    Department of Microbiology and Immunology, School of Medicine, University of California, Davis, 95616, USA
    Proc Natl Acad Sci U S A 102:18129-34. 2005
    ..Thus, the specific deficiency of PC defensins that characterizes ileal CD may compromise innate immune defenses of the ileal mucosa and initiate and/or perpetuate this disease...
  29. ncbi request reprint Human defensins in Crohn's disease
    Jan Wehkamp
    Department of Microbiology and Immunology, University of California, Davis, Calif, USA
    Chem Immunol Allergy 86:42-54. 2005
    ..The hypothesis of an impaired mucosal antibacterial activity is also consistent with the benefit from antibiotic or probiotic treatment in certain disease states...
  30. ncbi request reprint Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein
    Susanne Schinke
    Department of Rheumatology, University of Luebeck, Bad Bramstedt, Germany
    Inflamm Bowel Dis 10:763-70. 2004
    ..Inhibition of the antibiotic function mediated by the N-terminal region of BPI by these autoantibodies may contribute to a proinflammatory environment in IBD patients...
  31. ncbi request reprint Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease
    Jan Wehkamp
    Department of Microbiology and Immunology, University of California, Davis, CA 95616, USA
    J Leukoc Biol 77:460-5. 2005
    ..Thus, it can be speculated that decreased defensin levels lead to a weakened intestinal barrier function to intestinal microbes and might be crucial in the pathophysiology of Crohn's disease...
  32. ncbi request reprint 6-thioguanine-buried alive?
    Klaus R Herrlinger
    Gastroenterology 126:940-1; author reply 941-2. 2004
  33. ncbi request reprint Antimicrobial peptides in the skin
    Klaus Fellermann
    N Engl J Med 348:361-3; author reply 361-3. 2003